ADHD Treatment Portfolio Consolidated at $700 Million: U.S. Biotech Goes All-In on Rare Diseases

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) announced on March 16 that it has agreed to sell its injectable SDX portfolio—including AZSTARYS and KP1077—to Belgium’s Commave Therapeutics for approximately $50 million (about KRW 70 billion) and will concurrently withdraw the Delaware Court of Chancery litigation between the two companies.

Prior to closing the deal, Zevra fully repaid its outstanding debt of $63 million (approximately KRW 85 billion), becoming debt-free. The company plans to deploy its strengthened financial position to accelerate development and commercialization within its rare-disease pipeline.

Zevra recently partnered with U.S. genomics diagnostics firm GeneDx to launch a free genetic testing program for patients suspected of having Niemann-Pick disease type C. This initiative enhances access to exome-based diagnostics and has driven a sharp, short-term rise in Zevra’s share price.

Further cementing its role as a rare-disease specialist biotech, Zevra was added to the Nasdaq Biotechnology Index in 2024 and has begun U.S. commercialization of MIPLYFFA—the first FDA-approved therapy for Niemann-Pick disease type C.

Originally known as KemPharm, Zevra Therapeutics is a Nasdaq-listed developer of therapies for rare, hard-to-treat diseases, with a focus on oral and other innovative treatments targeting small patient populations.

With its flagship product MIPLYFFA now on the market, Zevra is broadening its impact across the rare-disease ecosystem through strategic genetic-testing partnerships and patient-awareness campaigns.